ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Retrospective evaluation of platelet indices and RAS mutations in patients with colon cancer
Abstract
Aims: Colon cancers are one of the most common cancer types in the world and cause significant mortality. The presence of RAS mutation is also associated with poor prognosis in colon cancers and plays an important role in the choice of treatment. Platelet indices, which have recently been evaluated with an easy-to-reach method, have been discussed as an inflammatory marker in many studies. In this study, it was aimed to investigate the relationship between platelet distribution width (PDW), colon cancer stage and the presence of RAS mutation.
Methods: File records of 132 patients who were followed up with the diagnosis of colon cancer in Kırıkkale University Faculty of Medicine, Department of Internal Medicine and Medical Oncology Department between January 1, 2015 and January 1, 2021 were retrospectively analyzed. Patients with RAS mutations and who did not receive chemotherapy were included in the study. Patients with and without RAS mutation were divided into two groups and their platelet index (especially PDW) values were compared. PDW values were compared according to the stages of the patients. The correlation between stage and PDW was examined.
Results: Of the 132 patients included in the study, 82 (62.1%) were male and 50 (37.9%) were female. Participants; 12 (9.1%) stage 1, 23 (17.4%) stage 2, 29 (22%) stage 3, 68 (51.5%) stage 4 colon cancer patients. There were no RAS mutations in 73 (55.3%) patients, and 59 (44.7%) patients had RAS mutations. There was no significant difference in PDW between the two groups with negative and positive RAS mutations (p=0.826). According to the stages; PDW values were significantly different between the four stages (X2=9.878, p=0.020).
Conclusion: In the study, PDW increased as the stage increased, but there was no significant relationship between RAS mutation and PDW. This was attributed to the fact that as the stage increases, the level of inflammation may be associated with an increase. Larger studies on this subject are needed.

Keywords : Platelet indices, colon cancer, RAS mutation

Download Article


1. Şahin S. Kanserde erken tanı ve tarama programları. Ege Tıp Dergisi.2015; 54(Suppl): 41-45.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Globalcancer statistics, 2012. CA: A Cancer J Clinicians. 2015; 65(2): 87-108.
3. Kumar A, Guss ZD, Courtney PT, et alEvaluation of the use of cancerregistry data for comparative effectiveness research. JAMA NetworkOpen. 2020;3(7):e2011985-e2011985.
4. Zeng M, Kikuchi H, Pino MS, Chung DC. Hypoxia activates the K-rasproto-oncogene to stimulate angiogenesis and inhibit apoptosis incolon cancer cells. Plos ONE. 2010; 5(6):e10966.
5. Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictivebiomarker for selecting anti-EGF receptor/pathway treatment.Biomarkers in Medicine. 2010; 4(4):535-541.
6. Kim DK, Kang B, Kim OY, et al. EVpedia: an integrated database ofhigh-throughput data for systemic analyses of extracellular vesicles. JExtracellular Vesicles. 2013; 2(1):20384.
7. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatouspolyposis (AFAP) a phenotypically and genotypically distinctivevariant of FAP. Cancer. 1995; 76(12):2427-2433.
8. Agrawal D, Newaskar V, Shrivastava S, Nayak PA. Externalmanifestations of Gardner’s syndrome as the presenting clinical entity.Case Reports. 2014; bcr2013200293.
9. Turcot J, Després JP, Pierre FS. Malignant tumors of the central nervoussystem associated with familial polyposis of the colon: report of twocases. Dis Colon Rectum. 1959;2(5):465-468.
10. Junquera LC, Carneıro J. Çeviri Editörü, Aytekin Y, Solakoğlu S, TemelHistoloji, Nobel Tıp Kitabevleri, 2010:225-236.
11. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer inulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-535.
12. Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, MeadeTW. Effect of daily aspirin on long-term risk of death due to cancer:analysis of individual patient data from randomised trials. Lancet. 2011;377(9759): 31-41.
13. Kao SC, Pavlakis N, Harvie R, et al. High Blood Neutrophil-to-lymphocyte ratio ıs an indicator of poor prognosis in malignantmesothelioma patients undergoing systemic therapy systemicinflammation in malignant mesothelioma.Clin Cancer Res.2010;16(23): 5805-5813.
14. Sakin A, Sahin S, Sakin A, et al. Mean platelet volume and plateletdistribution width correlates with prognosis of early colon cancer. JBUON. 2020; 25(1): 227-239.
15. Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count inpatients with colorectal cancer predicts tendency to metastases andpoor prognosis. Hepato-gastroenterol. 2012; 59(118): 1687-1690.
16. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Plateletsand granulocytes, in particular the neutrophils, form importantcompartments for circulating vascular endothelial growth factor.Angiogenesis. 2003; 6(4): 283-287.
17. Gu M, Zhai Z, Huang L, et al. Pre-treatment mean platelet volumeassociates with worse clinicopathologic features and prognosis ofpatients with invasive breast cancer. Breast Cancer. 2016; 23(5): 752-760.
18. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J SurgOncol. 2005; 91(3): 181-184.
19. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyteratio predicts chemotherapy outcomes in patients with advancedcolorectal cancer. British J Cancer. 2011; 104(8): 1288-1295.
20. Carriquiry LA, Piñeyro A. Should carcinoembryonic antigen be used inthe management of patients with colorectal cancer? Dis Colon Rectum.1999; 42(7): 921-929.
21. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Int J Cancer. 2014; 134(10): 2403-241.
22. Boonpipattanapong T, Chewatanakornkul S. Preoperativecarcinoembryonic antigen and albumin in predicting survival inpatients with colon and rectal carcinomas. J Clin Gastroenterol. 2006;40(7): 592-595.
23. Tumay V, Guner OS. The utility and prognostic value of CA 19-9and CEA serum markers in the long-term follow up of patients withcolorectal cancer. A single-center experience over 13 years. Ann ItalChir. 2020: 91(5): 498-503.
24. Gnanasampanthan G, Elsaleh H, Mccaul K, Iacopetta B. Ki-rasmutation type and the survival benefit from adjuvant chemotherapy inDukes’ C colorectal cancer. J Pathol. 2001; 95(5): 543-548.
25. Olariu A, Bartoş A, Bartoş D, et al. Evaluation of prognostic factors forcolon cancer. Chirurgia (Bucharest, Romania: 1990). 2012; 107(2): 174-179.
26. Chapuis PH, Dent OF, Fisher R, et al. A multivariate analysis of clinicaland pathological variables in prognosis after resection of large bowelcancer. J British Surg. 1985; 72(9): 698-702.
27. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138Iranian colorectal cancer patients. Int J Colorectal Dis. 2008; 23(7): 683-688.
28. Küçüköner M, Kaplan MA, İnal A, et al. Kolorektal kanserler: tekmerkez 12 yıllık sonuçları. J Clin Exp Invest. 2013; 4(2): 208-212.
29. Kutlu R, Demirbaş N, Börüban MC, Güler T. Sigara içmeye atfedilebilenkanser türleri ve sosyodemografik özellikleri.Türk Onkoloji Derg.2014;29(3): 81-88.
30. Sarı R, Durak D, Yazıcıoğlu MÖ, Gürer A. Kolon kanserlerindebilgisayarlı tomografinin lenf nodu tespitindeki rolü. Bozok Tıp Dergisi.2019; 9(2): 48-51.
31. Benedek Z, Boér ST, Bauer O, et al. An overview of five-year survivalin rectal cancer in relation to lymph node status. Chirurgia (Bucharest,Romania: 1990). 2020; 115(6): 747-755.
32. Ortega PM, Cienfuegos JA, Baixauli J, et al. Prognostic significance oflymph node count in high-risk node-negative colon carcinoma.Rev EspEnferm Dig. 2020;112: 609-614.
Article available in :
Volume 1, Issue 1, 2023
Page : 1-7
https://doi.org/10.51271/ICJIM-0001
Article Information
Received : 02 Şub 2023
Accepted : 17 Şub 2023
Published : 25 Şub 2023
Corresponding Author :

Merve Şanlıer: Department of Internal Medicine, Faculty of Medicine, Kırıkkale University, Kırıkkale, TURKEY

[email protected]
Citation : Şanlıer M, Yalçın S. Retrospective evaluation of platelet indices and RAS mutations in patients with colon cancer. Intercont J Int Med 2023; 1(1): 1-7

Read: 231
Cited: 0
Download : 219
_Footer